AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
ceftizoxime 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, cefalosporanic acid derivatives | 563 | 68401-81-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 4 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 93 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 260.82 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 0 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.20 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 2.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.72 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.50 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 81 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -1.521 | Moderate | 0.73 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 2.065 | Moderate | 0.73 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 1.589 | 10^-6 cm/s | Moderate | 0.73 |
| dh-clint | Dog hepatocyte intrinsic clearance | 2.399 | uL/min/10^6 cells | Moderate | 0.73 |
| dppb | Dog plasma protein binding (% unbound) | 62.240 | % | Moderate | 0.73 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 48.910 | % | Moderate | 0.73 |
| herg | hERG pIC50 | 4.181 | pIC50 | Moderate | 0.73 |
| hh-clint | Human hepatocyte intrinsic clearance | 1.445 | uL/min/10^6 cells | Moderate | 0.73 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.631 | uL/min/mg protein | Moderate | 0.73 |
| hppb | Human plasma protein binding (% unbound) | 40.010 | % | Moderate | 0.73 |
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT3,ALK,AURKA,AURKB,AURKC,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,DYRK3,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,HIPK2,IKBKB,ITK,JAK1,JAK2,KIT,MAP2K6,MAP3K14,MAP3K2,MAP3K21,MAP3K3,MAP3K7,MAP4K1,MAP4K3,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM1,PIM2,PIM3,PRKAA1,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2 | 74 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,CDK9,DYRK1B,EIF2AK3,EPHB4,GRK2,JAK2,MAP2K6,MAP3K14,MAPK7,MAPK8,PRKDC,STK33,SYK,TEK,TGFBR1,TTK,UHMK1 | 20 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 8.810 | Moderate | 0.73 | |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 2.541 | Moderate | 0.73 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 4.093 | Moderate | 0.73 | |
| mppb | Mouse plasma protein binding (% unbound) | 58.330 | Moderate | 0.73 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 2.317 | Moderate | 0.73 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 42.680 | % | Moderate | 0.73 |
| rat-kpuu-brain | Rat brain Kpuu | 0.011 | % | Moderate | 0.73 |
| rh-clint | Rat hepatocyte intrinsic clearance | 1.905 | uL/min/10^6 cells | Moderate | 0.73 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 92.040 | % | Moderate | 0.73 |
| rppb | Rat plasma protein binding (% unbound) | 38.360 | % | Moderate | 0.73 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 957.194 | uM | Moderate | 0.73 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 15, 1983 | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01DD07 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins |
| FDA CS | M0003827 | Cephalosporins |
| FDA EPC | N0000175488 | Cephalosporin Antibacterial |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:36047 | antibacterial drug |
Related Drugs by ATC class:
J01DD Third-generation cephalosporins 17 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Streptococcal meningitis | indication | 4510004 | DOID:11574 |
| Meningitis | indication | 7180009 | DOID:9471 |
| Septicemia due to Escherichia coli | indication | 9323009 | |
| Bacterial septicemia | indication | 10001005 | DOID:0040085 |
| Gonorrhea | indication | 15628003 | DOID:7551 |
| Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
| Acute gonococcal cervicitis | indication | 20943002 | DOID:10615 |
| Staphylococcal pneumonia | indication | 22754005 | |
| Streptococcal septicemia | indication | 29577008 | |
| Acute gonococcal urethritis | indication | 29864006 | |
| Pneumonia due to Streptococcus | indication | 34020007 | |
| Gonorrhea of rectum | indication | 42746002 | |
| Lower respiratory tract infection | indication | 50417007 | |
| Pneumonia due to Escherichia coli | indication | 51530003 | |
| Klebsiella cystitis | indication | 60867007 | |
| Acute gonococcal endometritis | indication | 65295003 | DOID:7527 |
| Urinary tract infectious disease | indication | 68566005 | |
| Haemophilus influenzae pneumonia | indication | 70036007 | |
| Infection due to Escherichia coli | indication | 71057007 | |
| Bacterial infection due to Serratia | indication | 71120004 | |
| Rhinoscleroma | indication | 72409005 | DOID:11336 |
| Septicemia due to Bacteroides | indication | 79587009 | |
| Septicemia due to Serratia | indication | 82091000 | |
| Infection of bone | indication | 111253001 | |
| Infectious disease of abdomen | indication | 128070006 | |
| Infection due to Enterobacteriaceae | indication | 128945009 | |
| Bacterial infection due to Klebsiella pneumoniae | indication | 186435004 | |
| Proteus pneumonia | indication | 195888009 | |
| Bacterial peritonitis | indication | 197171003 | |
| Pneumonia | indication | 233604007 | DOID:552 |
| Escherichia coli urinary tract infection | indication | 301011002 | |
| Proteus urinary tract infection | indication | 301012009 | |
| Streptococcus pyogenes infection | indication | 302809008 | |
| Bacterial urinary infection | indication | 312124009 | |
| Infectious disorder of joint | indication | 363162000 | |
| Infection due to Staphylococcus aureus | indication | 406602003 | |
| Osteomyelitis due to Staphylococcus aureus | indication | 428783003 | |
| Sepsis due to Staphylococcus aureus | indication | 448417001 | |
| Peptostreptococcus infection | indication | 135341000119101 | |
| Staphylococcus Peritonitis | indication | ||
| Skin and Skin Structure Serratia Infection | indication | ||
| E. Coli Peritonitis | indication | ||
| Streptococcus Osteomyelitis | indication | ||
| Proteus Mirabilis Osteomyelitis | indication | ||
| Peptostreptococcus Peritonitis | indication | ||
| Morganella Morganii Urinary Tract Infection | indication | ||
| Staphylococcus Aureus Joint Infection | indication | ||
| Skin and Skin Structure Peptococcus Infection | indication | ||
| Peptostreptococcus Joint Infection | indication | ||
| Staphylococcus Aureus Urinary Tract Infection | indication | ||
| Peptococcus Osteomyelitis | indication | ||
| Proteus Joint Infection | indication | ||
| Streptococcal Pelvic Inflammatory Disease | indication | ||
| Peptococcus Joint Infection | indication | ||
| Peptostreptococcus Osteomyelitis | indication | ||
| Bacteroides Joint Infection | indication | ||
| Skin and Skin Structure Proteus Infection | indication | ||
| Skin and Skin Structure Bacteroides Fragilis Infection | indication | ||
| H. Influenzae Meningitis | indication | ||
| Peptococcus Peritonitis | indication | ||
| Staphylococcus Epidermidis Skin and Skin Structure Infection | indication | ||
| Pelvic Inflammatory Disease with Neisseria Gonorrhea | indication | ||
| Serratia Urinary Tract Infection | indication | ||
| Klebsiella Pneumoniae Peritonitis | indication | ||
| Bacteroides Osteomyelitis | indication | ||
| E. Coli Pelvic Inflammatory Disease | indication | ||
| Streptococcal Joint Infection | indication | ||
| Pseudomonas Aeruginosa Urinary Tract Infection | indication | ||
| Enterobacter Pneumonia | indication | ||
| Streptococcal Peritonitis | indication | ||
| Bacteroides Peritonitis | indication | ||
| Providencia Urinary Tract Infection | indication | ||
| Bacteroides Pneumonia | indication | ||
| Pyrexia of unknown origin | off-label use | 7520000 | |
| Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
| Factor II deficiency | contraindication | 73975000 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Pseudomembranous enterocolitis | contraindication | 397683000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.58 | acidic |
| pKa2 | 13.14 | acidic |
| pKa3 | 3.25 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial penicillin-binding protein | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| Penicillin-binding protein 1A | Enzyme | WOMBAT-PK | |||||||
| Beta-lactamase | Enzyme | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| 4017998 | VUID |
| N0000179458 | NUI |
| D00923 | KEGG_DRUG |
| 68401-82-1 | SECONDARY_CAS_RN |
| 2192 | RXNORM |
| C0007560 | UMLSCUI |
| CHEBI:553473 | CHEBI |
| CHEMBL528 | ChEMBL_ID |
| CHEMBL1201019 | ChEMBL_ID |
| DB01332 | DRUGBANK_ID |
| D015296 | MESH_DESCRIPTOR_UI |
| 6533629 | PUBCHEM_CID |
| 10785 | IUPHAR_LIGAND_ID |
| 4743 | INN_ID |
| C43C467DPE | UNII |
| 4386 | MMSL |
| d00010 | MMSL |
| 002729 | NDDF |
| 004847 | NDDF |
| 372770006 | SNOMEDCT_US |
| 54577009 | SNOMEDCT_US |
| 5681006 | SNOMEDCT_US |
| 4017998 | VANDF |
| 4019666 | VANDF |
Pharmaceutical products:
None